Compare AGM & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | KOD |
|---|---|---|
| Founded | 1987 | 2009 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | N/A | 2018 |
| Metric | AGM | KOD |
|---|---|---|
| Price | $202.52 | $41.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $215.00 | $35.43 |
| AVG Volume (30 Days) | 116.4K | ★ 864.4K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $12.21 | N/A |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $136.57 | $4.39 |
| 52 Week High | $210.64 | $47.84 |
| Indicator | AGM | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 70.37 | 61.73 |
| Support Level | $165.60 | $39.37 |
| Resistance Level | N/A | $46.72 |
| Average True Range (ATR) | 4.80 | 3.07 |
| MACD | 0.31 | 0.62 |
| Stochastic Oscillator | 91.35 | 89.39 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.